CGM097 (CAS: 1313363-54-0) is an orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.
|
TGF-beta/Smad
TNF-alpha
